Patents Examined by Robert H Havlin
-
Patent number: 11980593Abstract: Disclosed herein are compositions and methods for delivering cannabidiol to subject in need of hypertension treatment. The disclosed compositions are orally delivered. Further disclosed are kits comprising the disclosed compositions as part of a method of delivering the cannabidiol-containing compositions.Type: GrantFiled: July 5, 2022Date of Patent: May 14, 2024Assignee: POVIVA CORP.Inventors: John Docherty, Christopher Andrew Bunka
-
Patent number: 11952362Abstract: The present disclosure provides compounds and compositions capable of treating cancer or an autoimmune disease, such as Crohn's disease, and methods of use thereof.Type: GrantFiled: July 22, 2019Date of Patent: April 9, 2024Assignee: The Regents of the University of CaliforniaInventors: Dimitrios Iliopoulos, Michael E. Jung, Jonghoon Kim, Jill M. Hoffman, Iordanes Karagiannides
-
Patent number: 11945792Abstract: The present invention relates to various crystalline forms of 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide. The present invention also relates to pharmaceutical compositions comprising the crystalline forms.Type: GrantFiled: March 3, 2021Date of Patent: April 2, 2024Assignee: Beijing Innocare Pharma Tech Co., LtdInventors: Xiangyang Chen, Zuopeng Wang, Liqin Yu
-
Patent number: 11926871Abstract: Provided herein are compositions and methods for generating phase-shift barcode oligonucleotides for library construction for next-generation sequencing. In some cases, barcode oligonucleotides are attached to particles or beads. Also provided are methods and kits for using the phase-shift barcode oligonucleotides in sequencing assays.Type: GrantFiled: March 29, 2021Date of Patent: March 12, 2024Assignee: Bio-Rad Laboratories, Inc.Inventors: Lucas Frenz, Jeremy Agresti
-
Patent number: 11884624Abstract: Disclosed herein are compounds of formula (I) and therapeutic methods of treatment with compounds of formula (I), wherein L1, L2, L4, R1, R4, R5, R6, and s are as defined in the specification. Compounds of formula (I) are EP4 agonists useful in the treatment of glaucoma, neuropathic pain, and related disorders.Type: GrantFiled: June 9, 2021Date of Patent: January 30, 2024Assignee: CAYMAN CHEMICAL COMPANY, INC.Inventors: Stephen Douglas Barrett, Fred Lawrence Ciske, Joseph Michael Colombo, Gregory William Endres, Bradlee David Germain, Andriy Kornilov, James Bernard Kramer, Adam Uzieblo, Kirk M. Maxey
-
Patent number: 11873267Abstract: Pharmaceutical compositions of the invention comprise functionalized N,N-dialkylamino phenyl ethers derivatives having a disease-modifying action in the treatment of diseases associated with lysosomal storage dysfunction that include Gaucher's disease, and any disease or condition involving lysosomal storage dysfunction.Type: GrantFiled: May 24, 2017Date of Patent: January 16, 2024Assignee: Temple University-Of The Commonwealth System of Higher EducationInventors: Magid A. Abou-Gharbia, Wayne E. Childers, Marlene A. Jacobson, Rong Fan, Rogelio L. Martinez
-
Patent number: 11834447Abstract: The Invention provides indole derivatives of Formula I: and pharmaceutically acceptable salts and solvates thereof, wherein R1e, R1f, A, X, Y, Z, and W4 are defined as set forth in the specification. The Invention also provides the use of compounds of Formula I and the pharmaceutically acceptable salts and solvates thereof to treat pain. In certain embodiments, the Compounds of the Invention are effective in treating a disorder responsive to blockade of one or more sodium channels.Type: GrantFiled: July 30, 2020Date of Patent: December 5, 2023Assignee: Purdue Pharma L.P.Inventors: Stephen M. Lynch, Jiangchao Yao, Jae Hyun Park, Laykea Tafesse
-
Patent number: 11771681Abstract: The present invention relates to compositions comprising N,N-dimethyltryptamine, deuterated N,N-dimethyltryptamine and/or partially deuterated N,N-dimethyltryptamine. In particular, the present invention relates to compositions comprising a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more deuterated N,N-dimethyltryptamine compound selected from ?,?-dideutero-N,N-dimethyltryptamine and ?,?,?,?-tetradeutero-N,N-dimethyltryptamine. Additional and alternative compositions of the present invention comprise a combination of N,N-dimethyltryptamine and 2% or more by weight of one or more partially deuterated N,N-dimethyltryptamine compound selected from ?,?,?-trideutero-N,N-dimethyltryptamine, ?,?-dideutero-N,N-dimethyltryptamine, and ?-deutero-N,N-dimethyltryptamine.Type: GrantFiled: June 2, 2020Date of Patent: October 3, 2023Assignee: SMALL PHARMA LTDInventors: Peter Rands, Zelah Joel, Tiffanie Benway
-
Patent number: 11752130Abstract: Disclosed are novel carboxylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a carboxyl or Carboxylic acid derivative containing compound.Type: GrantFiled: September 23, 2022Date of Patent: September 12, 2023Assignee: Enveric Biosciences Canada Inc.Inventors: Jillian M. Hagel, Peter J. Facchini, Chang-Chun Ling
-
Patent number: 11738009Abstract: The present disclosure is directed to novel compounds of Formula I and pharmaceutically acceptable salts, solvates, solvates of the salt and prodrugs thereof, useful in the prevention (e.g., delaying the onset of or reducing the risk of developing) and treatment (e.g., controlling, alleviating, or slowing the progression of) of cancer, including glioblastoma, bone cancer, head and neck cancer, melanoma, basal cell carcinoma, squamous cell carcinoma, adenocarcinoma, oral cancer, esophageal cancer, gastric cancer, intestinal cancer, colon cancer, bladder cancer, hepatocellular carcinoma, renal cell carcinoma, pancreatic cancer, ovarian cancer, cervical cancer, lung cancer, breast cancer, and prostate cancer. The compounds of the disclosure are selective antagonists of the EP4 receptor and useful treatment of various diseases that may be ameliorated with blockade of PGE2-mediated signaling.Type: GrantFiled: April 17, 2018Date of Patent: August 29, 2023Assignee: TEMPEST THERAPEUTICS, INC.Inventors: Yalda Bravo, Jason David Burch, Austin Chih-Yu Chen, Joe Fred Nagamizo
-
Patent number: 11725205Abstract: A method of amplifying a target polynucleotide, comprising: providing a template polynucleotide comprising a 5? hairpin, a target polynucleotide and a 3? hairpin, wherein the 5? hairpin comprises one or more non-canonical nucleotides; and contacting the template polynucleotide with a polymerase and canonical nucleotides, wherein the polymerase extends, using the canonical nucleotides, the target polynucleotide from its 3? end to form a first extended polynucleotide comprising the 5? hairpin at its 5? end and the complement of the 5? hairpin at its 3? end, wherein the complement of the 5? hairpin forms a 3? hairpin; and the polymerase extends the first extended polynucleotide from its 3? end to form a second extended polynucleotide comprising the 5? hairpin at its 5? end and the complement of the 5? hairpin at its 3? end, wherein the complement of the 5? hairpin forms a 3? hairpin.Type: GrantFiled: May 14, 2019Date of Patent: August 15, 2023Assignee: Oxford Nanopore Technologies PLCInventor: James White
-
Patent number: 11726097Abstract: Characterization of the binding dynamics at the interface between any two proteins that specifically interact plays a role in myriad biomedical applications. The methods disclosed herein provide for the high-throughput characterization of the specific interaction at the interface between two protein binding partners and the identification of functionally significant mutations of one or both protein binding partners. For example, the methods disclosed herein may be useful for epitope and paratope mapping of an antibody-antigen pair, which is useful for the discovery and development of novel therapies, vaccines, diagnostics, among other biomedical applications.Type: GrantFiled: September 2, 2022Date of Patent: August 15, 2023Assignee: A-Alpha Bio, Inc.Inventors: David Younger, David Colby, Randolph Lopez, Michael Wittekind
-
Patent number: 11718592Abstract: The present invention relates to a compound of formula (1) wherein Q1 is halogen atom, Q2 is hydrogen atom, etc., X, Y, and Z are nitrogen atom or oxygen atom, and R1 has a given structure, or a pharmaceutically acceptable salt thereof, and a medicament comprising the compound for treating and/or preventing a disease such as epilepsy.Type: GrantFiled: September 16, 2022Date of Patent: August 8, 2023Assignee: Sumitomo Pharma Co., Ltd.Inventors: Yoshiaki Isobe, Tomoyuki Tanaka, Hirotaka Miyachi
-
Patent number: 11672774Abstract: The present invention relates to the field of cancer therapy. Specifically, provided are methods of treating Squamous Cell Carcinoma in a subject with a farnesyltransferase inhibitor (FTI) that include determining whether the subject is likely to be responsive to the FTI treatment based on the expression level of H-Ras.Type: GrantFiled: September 28, 2021Date of Patent: June 13, 2023Assignee: Kura Oncology, Inc.Inventors: Francis Burrows, Yi Liu
-
Patent number: 11642342Abstract: Provided herein are pharmaceutical combinations, compositions, and methods of using a compound with estrogen receptor (ER) degradation activity, such as a compound of formula (I) or a tautomer, stereoisomer or a mixture of stereoisomers, or a pharmaceutically acceptable salt, or hydrate thereof, wherein R1, Y, R22, R33, R2, p, X3, X4, and Z are defined herein and a cyclin-dependent kinase (CDK) inhibitor.Type: GrantFiled: January 4, 2021Date of Patent: May 9, 2023Assignee: ACCUTAR BIOTECHNOLOGYInventors: Jie Fan, Yimin Qian, Wei He
-
Patent number: 11639519Abstract: Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.Type: GrantFiled: July 25, 2022Date of Patent: May 2, 2023Assignee: University of WashingtonInventors: Georg Seelig, Richard Muscat, Alexander B. Rosenberg
-
Patent number: 11634751Abstract: Methods of uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are provided. Kits for uniquely labeling or barcoding molecules within a cell, a plurality of cells, and/or a tissue are also provided. The molecules to be labeled may include, but are not limited to, RNAs, cDNAs, DNAs, proteins, peptides, and/or antigens.Type: GrantFiled: December 15, 2020Date of Patent: April 25, 2023Assignee: University of WashingtonInventors: Georg Seelig, Richard Muscat, Alexander B. Rosenberg
-
Patent number: 11629166Abstract: The invention relates to compounds, compositions and polymers comprising a first component adapted to promote germination of Clostridium difficile (C. diff) and a second component which acts as an antimicrobial agent. Said compounds, compositions and polymers are useful for destroying C. diff where conventional antimicrobial agents are unsuccessful. The compositions can be formulated as coating or materials which actively destroy C. diff which come into contact with it. The germination promotion is induced by bile salts. The invention also relates to the use of such materials as a treatment for C. diff associated diseases and toxic megacolon.Type: GrantFiled: December 23, 2019Date of Patent: April 18, 2023Assignee: Aston UniversityInventors: Daniel Lee Rathbone, Tony Worthington, Sahar Al-Malaika, Matthew Justin Hird, Alexandria Rose Quayle
-
Patent number: 11624062Abstract: Methods, systems and related compositions are provided to perform single-cell marking of a nucleic acid and/or protein in a sample based on in-cell or in-organelle barcoding of nucleic acid and/or protein complexes of the cell or organelle; the methods and systems herein described are configured to provide in-cell or in-organelle single-cell marked nucleic acid and/or protein complexes comprising a single-cell, cell-specific, or a single-cell organelle-specific marker.Type: GrantFiled: September 25, 2018Date of Patent: April 11, 2023Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGYInventors: Rustem F. Ismagilov, Matthew S. Curtis, Mary Arrastia, David A. Selck, Mitchell Guttman
-
Patent number: RE49847Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.Type: GrantFiled: January 5, 2022Date of Patent: February 27, 2024Assignees: Novartis AG, The Trustees of the University of PennsylvaniaInventors: Barbara Brannetti, Jennifer Brogdon, Boris Engels, Brian Granda, Lu Huang, Ming Lei, Na Li, Jimin Zhang, Carla Guimaraes, Saar Gill, Marco Ruella, Regina M. Young